Blood lipids (or blood fats) are lipids in the blood, either free or bound to other molecules. They are mostly transported in a protein capsule, and the density of the lipids and type of protein determines the fate of the particle and its influence on metabolism.
Lipids float in the blood and can attach themselves to the walls of arteries causing atherosclerosis
Nutritionist was found that a diet containing Chromium source would eliminate this impairment and blood glucose levels would return to normal.
Glucose tolerance factor is believed to be a complex of trivalent chromium with two moles of nicotinic acid (niacin) and at least one mole of an amino acid. For example, as suggested by Mertz.
A total blood lipid profile gives you the best possible statistical indication of your all round cardiovascular disease (CVD) risk. According to research, to come as close as possible to eliminating any threat of heart disease and stroke, your blood lipid profile would look like this (normal blood lipid profile):
* total cholesterol below 150 mg/dl
* total low-density lipoproteins (LDL) below 130 mg/dl
* total high-density lipoproteins HDL) above 40 mg/dl
* a ratio of LDL divided by HDL 3 to 1 or lower
* total triglycerides below 150 mg/dl
So, what you want to shoot for is low total cholesterol, low triglycerides, low LDL, high HDL and good LDL to HDL ratio. Achieving these good biomarkers on your blood lipid profile should pay off in hearty dividends.
GTF chromium is named for the way it interacts with insulin. Once absorbed, Chromium becomes incorporated into a compound called GTF (Glucose Tolerance Factor); which improves the body's sensitivity to insulin, and thus makes metabolism more efficient.
This is due to the central role insulin plays in regulating energy and metabolism. Insulin signals cells to absorb nutrients like sugar and amino acids when they're present in the bloodstream. Uptake of these nutrients allows them be used for growth, repair and energy.
When insulin function is poor from a lack of chromium or any other reason, uptake is impaired. When nutrients do not get taken up by cells completely, they must then be stored as additional body fat.
GTF chromium may also improve blood lipid profiles such as those for triglycerides4 and LDL cholesterol.
This review summarizes the results of 15 controlled studies supplementing defined Cr(III) compounds to subjects with impaired glucose tolerance. Three of these (3-4 mumol Cr/d for > 2 mo) produced no beneficial effects: serum glucose, insulin and lipid concentrations remained unchanged.
The remaining 12 interventions improved the efficiency of insulin or the blood lipid profile of subjects (ranging from malnourished children and healthy middle-aged individuals to insulin-requiring diabetics). In addition, three cases of impaired glucose tolerance after long-term total parenteral alimentation responding to Cr supplementation have been reported.
Chromium potentiates the action of insulin in vitro and in vivo; maximal in vitro activity requires a special chemical form, termed Glucose Tolerance Factor and tentatively identified as a Cr-nicotinic acid complex. Its complete structural identification is a major challenge to chromium research.
The development and validation of a procedure to diagnose chromium status is the second challenge. Such a test would allow the assessment of incidence and severity of deficiency in the population and the selection of deficiency in the population and the selection of chromium-responsive individuals.
The third challenge is the definition of chromium's mode of action on parameters of lipid metabolism that have been reported from some studies but not others. Future research along these lines might establish whether chromium deficiency is a factor in the much discussed "Syndrome X" of insulin resistance.
Source : U.S. Department of Agriculture, Beltsville Human Nutrition Research Center, MD 20705.
Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. This source was taken from The Funagata Diabetes Study. M Tominaga, H Eguchi, H Manaka, K Igarashi, T Kato and A Sekikawa, Department of Laboratory Medicine, Yamagata University School of Medicine, Japan.
~end
No comments:
Post a Comment